SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Care-plan review) — Isaac Newton

PatientIsaac Newton
Date of birth1976-01-04
IdentifiersMRN HR-EN011-SYN; SSN (made up) 000-11-6840
Document date2026-10-29
AuthorRupert Okonkwo-Fairbanks, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-week depression and mercury exposure review. [S]

History of Present Illness

Mr. Newton returns three weeks after starting sertraline 50 mg and a month after removal from exposure. Mild nausea in the first few days settled; he has had no other side effects and has missed no doses. He has had three sessions of cognitive behavioral therapy. He sleeps about five and a half hours, keeps the sleep window, and no longer dozes in the evening. He eats three meals a day. He has written to apologize to the friends he accused and has had warm replies; he no longer believes anyone was plotting against him. He is teaching fully and has begun to answer letters again. He has had no thoughts of death or of harming himself or anyone else. The safety office has not yet re-measured the laboratory after its cleaning, so it remains closed. He brought his 24-hour urine collection this morning. [S]

ElementDetail
MedicationSertraline 50 mg for three weeks; no side effects now
PsychotherapyThree CBT sessions
SleepAbout five and a half hours; no evening dozing
Suspicious ideasResolved; apologies made and accepted
ExposureNone for a month; laboratory still closed
PHQ-914, down from 20

Review of Systems

SystemResultFinding
ConstitutionalPositiveAppetite better; weight 64.8 kg
Ears, nose, mouth, and throatNegativeNo gum or mouth symptoms
NeurologicalNegativeNo tremor, numbness, or headache
PsychiatricPositiveMood lifting but still low most mornings; no suicidal thoughts, elevated mood, or agitation

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Sertraline 50 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morningOral route2026-10-08activeS
Acetaminophen 500 mg oral tablet, one or two tablets by mouth every 6 hours as needed for aches or fever, no more than 3 g a dayOne or two tablets every 6 hours as needed; no more than six tablets a dayOral route2026-10-15 to 2026-10-22completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-29Body height170cmS
2026-10-29Body weight64.8kgS
2026-10-29Body mass index (BMI) [Ratio]22.4kg/m2S
2026-10-29Systolic blood pressure118mm[Hg]S
2026-10-29Diastolic blood pressure74mm[Hg]S
2026-10-29Heart rate72/minS
2026-10-29Respiratory rate14/minS
2026-10-29Body temperature36.6CelS
2026-10-29Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-29Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]14{score}S
2026-10-29Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]7{score}S
2026-10-29Mercury [Mass/volume] in Blood3.1ug/L95th percentile of US adults below 5 ug/L (ATSDR); 50 ug/L or more is the threshold for symptoms of toxicityNormalS
2026-10-29Mercury [Mass/volume] in 24 hour Urine31ug/LBackground below 2 ug/L (95th percentile of adults); below 20 ug/L not associated with effects (ATSDR)HighS
2026-10-29Mercury/Creatinine [Mass Ratio] in 24 hour Urine27ug/g{creat}Occupational biological exposure index 20 ug/g creatinineHighS

Physical Exam

Vital signs recorded on 2026-10-29; see the Vital Signs section. [S]

SystemFinding
GeneralBetter color; tidier
MouthGums healthy
NeurologicalNo tremor; spiral drawing normal
Mental statusEngaged, at times humorous; mood "lighter"; affect more reactive; no suspicious or fixed false beliefs; no suicidal or homicidal ideation

Problems

ProblemClinical statusVerificationCodeProvenance
A year of poor sleep and poor appetite with 4 kg weight loss, two weeks of near-total sleeplessness, low spirits, and suspicious thoughts that colleagues and friends were plotting against him, now partly doubted; under evaluation for depression, a toxic cause, and other medical causesresolvedconfirmed R45.89S — Synthetic presenting concern echoing the poor sleep, poor appetite, distress, and retracted suspicions documented in his letters of September 1693; superseded by the diagnoses at the second visit.
Occupational exposure to elemental and inorganic mercury, with lesser exposure to lead, antimony, and arsenic compounds, from heating metals in an unventilated private laboratoryactiveconfirmed Z57.5S — Synthetic modern exposure echoing his documented chemical and alchemical work with metals, including mercury; no level of historical exposure is asserted.
Major depressive disorder, single episode, severe, without psychotic features (PHQ-9 20 at intake): a year of poor sleep and appetite with weight loss, low mood, poor concentration, and suspicious ideas held with partial insight; medical causes excluded; the contribution of low-level mercury exposure is uncertainactiveconfirmed F32.2S — Synthetic modern diagnosis. His sleeplessness, poor appetite, distress, and melancholy in 1693 are documented (D); calling them major depression is a modern reading, and mercury poisoning and other explanations proposed later are disputed (R).
Chronic insomnia comorbid with depression: sleep onset and maintenance difficulty for a year, with two weeks of near-total sleeplessness before intakeactiveconfirmed G47.00S — Synthetic diagnosis echoing his documented sleeplessness.
Raised urine mercury from occupational exposure (24-hour urine 46 ug/L, 41 ug/g creatinine; blood 9.4 ug/L) without tremor, gingivitis, erethism, neuropathy, or kidney injury; below the levels linked to overt toxicityactiveconfirmed R82.6S — Synthetic result echoing his documented work with mercury; it does not assert that he was poisoned (see CLM-0011, R, disputed).
Acute viral upper respiratory infection (common cold) with a low-grade fever, sore throat, and cough, a week after starting sertraline; resolvedresolvedconfirmed J06.9S — Synthetic intercurrent illness at an unscheduled visit; it echoes, without asserting, his documented mention of a distemper that was epidemical that summer (CLM-0008).

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyPHQ-9Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuationCompleted today14, down from 20 (30 percent); item 9 scored 0
SurveyGAD-7With the PHQ-9 when anxiety accompanies depressionCompleted today7, down from 11
SurveySuicide and violence risk reassessment (C-SSRS Since Last Visit, PHQ-9 item 9, and thoughts of harming others)Every visit during active treatmentCompleted todayNo suicidal thoughts, intent, plan, or behavior; no thoughts of harming others; PHQ-9 item 9 scored 0
Medication safetySSRI tolerability check two weeks after starting2 weeks after starting and after each dose changeCompleted todayDone at the preventive visit two weeks after the start (no side effects) and again today
Medication safetyAdherence and adverse-effect reviewEvery visit during active treatmentCompleted todayNo missed doses; early nausea resolved; no bleeding, restlessness, or sexual side effects
Laboratory24-hour urine mercury with creatinine correction, and blood mercuryAt the exposure assessment, then 4 to 6 weeks after removal and at 3 monthsCompleted todayUrine 31 ug/L and 27 ug/g creatinine, falling; blood 3.1 ug/L, normal; next at three months
LaboratoryKidney function and urine proteinAt the exposure assessment and at 3 monthsDueNormal at intake; due at three months
ExaminationSigns of mercury toxicity: tremor (postural and intention), handwriting, gums and mouth, erethism, peripheral neuropathyAt the exposure assessment and at each follow-up while levels are raisedCompleted todayNo tremor, gingivitis, or neuropathy
Self-managementWorkplace hazard control: re-measurement of mercury vapor after decontaminationAfter decontamination and before any return to the laboratoryDeferredMissed: the safety office planned to re-measure the laboratory within two weeks of cleaning, but has not yet done so. No harm: the laboratory has stayed closed, he has had no exposure, and his urine mercury is falling. Corrective action: the clinic wrote to the safety office asking for the measurement and the fume-hood installation date, and his return to laboratory work stays on hold until both are confirmed
Medication safetyChelation and provoked (chelator-challenge) urine testingOnly for symptomatic patients with high levels, decided with a medical toxicologistNot indicatedUrine mercury below 100 ug/L with no tremor, gingivitis, or kidney injury; removal from exposure comes first, and provoked testing is not valid
ExaminationWeight and nutritionEvery visit while weight is below his usualCompleted today64.8 kg, up 1.0 kg since the diagnosis visit; three meals a day
Self-managementPsychotherapy, sleep, and activityEvery visit during active treatmentCompleted todayThree CBT sessions; sleep window widened; teaching fully; walks most days
LaboratoryLithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS)Only on those drugsNot indicatedTreated with an SSRI only; no antipsychotic, because there are no psychotic features

Goal progress:

Guideline basis: CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016); Evaluating Mercury Exposure: Information for Health Care Providers (2018); NIOSH Pocket Guide to Chemical Hazards: Mercury compounds [except (organo) alkyls] (as Hg) (2026); American College of Medical Toxicology Position Statement on Post-Chelator Challenge Urinary Metal Testing (2010); Use and Misuse of Metal Chelation Therapy (McKay CA, editorial) and Recommendations for Provoked Challenge Urine Testing (Ruha AM), proceedings of the ACMT symposium (2013)

Follow-up: Depression review in three weeks; urine mercury and kidney tests at three months; second zoster dose in two to six months. [S]